{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:03:42Z","timestamp":1783569822772,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Open Project of Key Laboratory of Hematology, Guangxi Medical University","award":["No. GXHKL202402"],"award-info":[{"award-number":["No. GXHKL202402"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15719-7","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:34:47Z","timestamp":1770773687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of 50\u00a0mg versus 100\u00a0mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-6847","authenticated-orcid":false,"given":"Fang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6276-1989","authenticated-orcid":false,"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"10314","key":"15719_CR1","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","volume":"398","author":"J Cortes","year":"2021","unstructured":"Cortes J, Pavlovsky C, Sau\u00dfele S. Chronic myeloid leukaemia. Lancet. 2021;398(10314):1914\u201326.","journal-title":"Lancet"},{"issue":"18","key":"15719_CR2","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1001\/jama.2025.0220","volume":"333","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: A review. JAMA. 2025;333(18):1618\u201329.","journal-title":"JAMA"},{"key":"15719_CR3","doi-asserted-by":"publisher","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","volume":"49","author":"AEG Osman","year":"2021","unstructured":"Osman AEG, Deininger MW. Chronic myeloid leukemia: modern therapies, current challenges and future directions. Blood Rev. 2021;49:100825.","journal-title":"Blood Rev"},{"issue":"14","key":"15719_CR4","doi-asserted-by":"publisher","first-page":"e35953","DOI":"10.1002\/cncr.35953","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, et al. Management of chronic myeloid leukemia in 2025. Cancer. 2025;131(14):e35953.","journal-title":"Cancer"},{"issue":"1","key":"15719_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-022-01309-0","volume":"15","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2022","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Breccia M, Jabbour E, Mauro M, Cortes JE. A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase. J Hematol Oncol. 2022;15(1):90.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"15719_CR6","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1080\/0284186X.2021.1971292","volume":"60","author":"F Stagno","year":"2021","unstructured":"Stagno F, Breccia M, Annunziata M, Trawinska MM, Iurlo A, Sgherza N, et al. Long term follow-up of frontline dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta Oncol. 2021;60(11):1527\u201333.","journal-title":"Acta Oncol"},{"issue":"20","key":"15719_CR7","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-Year study results of DASISION: the dasatinib versus Imatinib study in Treatment-Na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333\u201340.","journal-title":"J Clin Oncol"},{"issue":"9","key":"15719_CR8","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"NP Shah","year":"2016","unstructured":"Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am J Hematol. 2016;91(9):869\u201374.","journal-title":"Am J Hematol"},{"issue":"1","key":"15719_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3324\/haematol.2018.188987","volume":"104","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, et al. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. 2019;104(1):93\u2013101.","journal-title":"Haematologica"},{"issue":"8","key":"15719_CR10","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371.","journal-title":"Leukemia"},{"key":"15719_CR11","doi-asserted-by":"publisher","first-page":"1146108","DOI":"10.3389\/fonc.2023.1146108","volume":"13","author":"F Cheng","year":"2023","unstructured":"Cheng F, Li Q, Cui Z, Hong M, Li W, Zhang Y. Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: from clinical trials to real-life settings. Front Oncol. 2023;13:1146108.","journal-title":"Front Oncol"},{"issue":"24","key":"15719_CR12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531\u201341.","journal-title":"N Engl J Med"},{"issue":"11","key":"15719_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.26689","volume":"97","author":"E Jabbour","year":"2022","unstructured":"Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, et al. Low-dose dasatinib 50\u00a0mg\/day versus standard-dose dasatinib 100\u00a0mg\/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022;97(11):1413\u20138.","journal-title":"Am J Hematol"},{"issue":"13","key":"15719_CR14","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cncr.31357","volume":"124","author":"K Naqvi","year":"2018","unstructured":"Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, et al. Early results of lower dose dasatinib (50\u00a0mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018;124(13):2740\u20137.","journal-title":"Cancer"},{"issue":"1","key":"15719_CR15","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/cncr.32504","volume":"126","author":"K Naqvi","year":"2020","unstructured":"Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50\u00a0mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126(1):67\u201375.","journal-title":"Cancer"},{"issue":"8","key":"15719_CR16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39(8):1797\u2013813.","journal-title":"Leukemia"},{"key":"15719_CR17","doi-asserted-by":"publisher","first-page":"797881","DOI":"10.3389\/fphar.2021.797881","volume":"12","author":"S He","year":"2021","unstructured":"He S, Bian J, Shao Q, Zhang Y, Hao X, Luo X, et al. Therapeutic drug monitoring and individualized medicine of dasatinib: focus on clinical pharmacokinetics and pharmacodynamics. Front Pharmacol. 2021;12:797881.","journal-title":"Front Pharmacol"},{"issue":"10","key":"15719_CR18","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1007\/s11095-023-03603-z","volume":"40","author":"S He","year":"2023","unstructured":"He S, Zhao J, Bian J, Zhao Y, Li Y, Guo N, et al. Population pharmacokinetics and pharmacogenetics analyses of dasatinib in Chinese patients with chronic myeloid leukemia. Pharm Res. 2023;40(10):2413\u201322.","journal-title":"Pharm Res"},{"key":"15719_CR19","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.2147\/DDDT.S521260","volume":"19","author":"F Cheng","year":"2025","unstructured":"Cheng F, Cui Z, Li Q, Wang L, Zhang Y, Li W. Dasatinib dose optimization based on therapeutic drug monitoring in patients with chronic-Phase chronic myeloid leukemia. Drug Des Devel Ther. 2025;19:4311\u201320.","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"15719_CR20","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","volume":"8","author":"K Murai","year":"2021","unstructured":"Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8(12):e902\u201311.","journal-title":"Lancet Haematol"},{"key":"15719_CR21","unstructured":"Paul La Ros\u00e9e MP, Fabisch C, Brioli A, Teichmann L, Saussele S, Waller C, et al. Improved tolerability with dasatinib 5 days compared to 7 days per week in patients with chronic myeloid leukemia in cheonic phase. 2024 EHA 2024:abs24-422276; S422172."},{"key":"15719_CR22","doi-asserted-by":"crossref","unstructured":"Shivangi Sharma PP, Kiran SV, Tayde A, Suresh B, Yonzone P, Kuncheria T, et al. Early Results of comparison of low-dose generic dasatinib (50 MG\/Day) versus imatinib (400 MG\/Day) in newly diagnosed chronic Phase chronic myeloid leukemia: Real-world evidence from a single-center, randomized controlled study from India. 2025 ASH 2025:abs25-13194.","DOI":"10.1182\/blood-2025-5562"},{"key":"15719_CR23","doi-asserted-by":"crossref","unstructured":"Rishi Dhawan NN, Jasmita Dass GK, Viswanathan M, Aggarwal P, Kumar. Manoranjan Mahapatra. An open label randomized Study of low dose dasatinib (50\u00a0mg OD) vs standard dose dasatinib (100\u00a0mg OD) vs standard dose imatinib (400\u00a0mg OD) as upfront therapy in patients with newly diagnosed CML-CP. 2025 ASH 2025:abs25\u201312432.","DOI":"10.1182\/blood-2025-5560"},{"key":"15719_CR24","doi-asserted-by":"publisher","first-page":"132216","DOI":"10.1016\/j.ijcard.2024.132216","volume":"410","author":"S Tan","year":"2024","unstructured":"Tan S, Baggio D, Porch K, Nerlekar N, Shortt J, Ko B. An association between Dasatinib, elevated left atrial pressure and pleural effusion. Int J Cardiol. 2024;410:132216.","journal-title":"Int J Cardiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15719-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15719-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:53:22Z","timestamp":1773831202000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15719-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15719"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15719-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study has been approved by the institutional ethics committee of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China) ([2021]1039-01). For the retrospective cohort: the the Institutional Ethics committee of Tongji Medical College, Huazhong University of Science and Technology granted a waiver of informed consent for the analysis of anonymized historical data. For the prospective cohort: all participants provided written informed consent prior to data collection. This study was conducted in accordance with the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"367"}}